AI assistant
Sending…
Sonoma Pharmaceuticals, Inc. — Director's Dealing 2012
Aug 27, 2012
35312_dirs_2012-08-27_d3decbe3-c3ef-4c1f-a2dc-cde9daccd7d0.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Oculus Innovative Sciences, Inc. (OCLS)
CIK: 0001367083
Period of Report: 2012-08-24
Reporting Person: Alton Gregg H (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2012-08-24 | Stock Option (Right to Buy) | $0.93 | A | 30405 | Acquired | 2022-08-24 | Common Stock (30405) | Direct |
Footnotes
F1: The option shall be fully vested as of the date of grant.
F2: The option was granted by the Issuer as compensation for serving on the Issuer's Board of Directors.
More from Sonoma Pharmaceuticals, Inc.
Capital/Financing Update
2026
Apr 30
Capital/Financing Update
2026
Apr 27
Capital/Financing Update
2026
Apr 17
Regulatory Filings
2026
Apr 9
Interim / Quarterly Report
2026
Feb 10
Director's Dealing
2026
Feb 9
Board/Management Information
2026
Jan 28
Investor Presentation
2026
Jan 12
Director's Dealing
2026
Jan 2
Director's Dealing
2026
Jan 2